Classifications

• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
  • A61K9/00—Medicinal preparations characterised by special physical form
  • A61K9/0012—Galenical forms characterised by the site of application
  • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
  • A61K31/00—Medicinal preparations containing organic active ingredients
  • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
  • A61K31/19—Carboxylic acids, e.g. valproic acid
  • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
  • A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
  • A61K31/198—Alpha-amino acids, e.g. alanine or edetic acid [EDTA]
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
  • A61K31/00—Medicinal preparations containing organic active ingredients
  • A61K31/33—Heterocyclic compounds
  • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
  • A61K31/365—Lactones
  • A61K31/375—Ascorbic acid, i.e. vitamin C; Salts thereof
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
  • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
  • A61P31/12—Antivirals
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
  • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
  • A61P31/12—Antivirals
  • A61P31/14—Antivirals for RNA viruses

Definitions

• the present invention relates to a method for preventing infection with various viruses, and a preparation that can be used in the method.
• Viruses are primitive organisms that can only grow in living cells of animals, and are distinguished from bacteria in that they have only genetic information of either DNA or RNA.
• Examples of viral infections caused by virus infection include smallpox, herpes, and hepatitis B caused by DNA viruses, and measles, influenza, and Japanese encephalitis caused by RNA viruses.
• S ARS severe acute respiratory syndrome
• the vaccine is obtained by growing a virus that is expected to spread by hatching chicken egg culture, collecting a large amount of allantoic fluid containing the virus, and inactivating and attenuating the virus by formalin treatment or the like. Vaccines are no longer infectious, ie they cannot grow in the host, but can serve as antigens and produce antibodies specific to each virus. The antibody then captures and neutralizes the active virus. By this mechanism, vaccines can prevent viral transmission. ⁇
• the immunity generated by vaccination with Kuching lasts about one year, and the efficacy of vaccination is estimated to be 70-80%.
• RNA viruses undergo drastic structural changes. For example, it has been reported that the nucleotide sequence of a coronavirus that causes SARS was already different between Hong Kong and Taiwan. Thus, even if a vaccine is developed that is effective in preventing SARS, rapid structural changes in the virus can quickly render the vaccine ineffective, making this a promising one.
• vaccination with vaccines may cause side effects, and there are restrictions such as those who have egg hypersensitivity must avoid preventive breeding.
• a swine influenza pandemic (nationwide and even an international pandemic across several powers) was about to occur in the United States in 1976, the US federal government The government prepared a vaccine with a $ 500,000 grant and inoculated millions of people.
• the epidemic of concern did not occur, and vaccinations were interrupted prematurely, with severe side effects on the vaccinated person.
• the most severe of these side effects was Guillain-Palais syndrome, which causes muscle weakness and severe sensory paralysis.
• a method of inhibiting viral infection without using a vaccine for example, a method of administering a serine leukocyte protease inhibitor or an analog or derivative thereof to a subject to be prevented in an amount sufficient to prevent the infection is known.
• This method is effective for infectious diseases caused by retrovirus, such as cancer and autoimmune diseases, and can be preferably used as a countermeasure for human immunodeficiency virus infection, particularly including acquired immunodeficiency syndrome group. It is said that.
• An object of the present invention is to solve the above problems, and an object of the present invention is to provide a novel method capable of effectively preventing virus infection without using a vaccine.
• the present invention relates to a method for preventing viral infection, which comprises administering large amounts of vitamin C and arginine.
• the present invention also relates to a virus infection preventive agent comprising vitamin C and arginine coated with a coating.
• Vitamin C is a water-soluble vitamin that is involved in redox reactions in vivo.
• animals such as humans and monkeys cannot synthesize vitamin C because they do not have enzymes involved in the reaction of the intermediate.
• hypoascorbic acidemia or inducible ascorbic acid hypoxia occurs, it is generally due to disorders of the immune system, disorders of the blood coagulation system, and decreased adrenal function. It can cause stress-related dysfunction, impaired collagen production, nervous system dysfunction, reduced immune function, and reduced cancer detoxification ability.
• the present inventors have found that administration of a large amount of vitamin C in combination with arginine can prevent viral infection (particularly coronavirus infection that causes SARS), and based on this finding, completed the present invention. .
• Vitamin C constantly autoxidizes and releases radicals, and copper, one of the micronutrients essential for living organisms, is chelated by a large amount of vitamin C to form a metal complex, generating strong active oxygen. And the powerful active oxygen radical generated by this vitamin C and a small amount of ⁇ becomes an active substance in the method for preventing virus infection of the present invention.
• vitamin C in the method for preventing viral infection of the present invention is to act on the viral base sequence to cleave and inactivate it.
• Viruses invade their own base sequences into cells and parasitize and proliferate, but upon entry into the cells, the base sequences are removed from their outer shell (envelope) and inner shell (protein layer). Release to expose DNA and RNA.
• the exposed base sequence is attacked by the above-mentioned active oxygen radical derived from vitamin C, and a part thereof is cleaved.
• the virus escapes from the infested cell to invade other cells.At the time of this escape, DNA and RNA are exposed, and the exposed base sequence is caused by the radicals of active oxygen. Under attack.
• vitamin C in the method for preventing viral infection of the present invention is to return a peroxidized organism to a normal reduced state.
• the virus When a virus enters a living body, the virus causes inflammation in various organs of the living body, resulting in a peroxidized state. If the peroxidation state is left unchecked, the virus infection will progress and eventually the virus will develop. However, if the peroxidation state caused by inflammation is returned to the reduced state at the very early stage when the virus enters the living body, the virus infection does not progress further and the virus infection can be prevented as a result. And
• vitamin C also has the effect of enhancing the immune function, which is a natural defense mechanism in the human body. In this effect, vitamin C can help leukocytes, which play a central role in immune function, and enhance immune function.
• Vitamin C dosage may vary depending on the subject's body weight, gender, age, health condition, and other conditions, but at least 300 to 500 mg / kg g / day (20 g / day or more) for antiviral measures. It is.
• the disorder can be returned to a normal state by administering at least 100 Omg / kg / day of vitamin C.
• the required amount of vitamin C is considered to be about lmg / kgZ days, and even at the highest, it is less than 20 Omg / 7 days. It is easy to understand how large the amount of vitamin C used in the treatment is. This dose is for oral administration.
• the upper limit of the dose of vitamin C is determined by the maximum tolerated dose of vitamin C in the intestine of the subject.
• the maximum tolerated vitamin C in the intestine is the maximum amount of vitamin C that can be taken orally without unpleasant diarrhea, and is about 4 to 15 g per day for normal humans. However, this amount varies from subject to subject and from time to time for the same subject. It has been reported that the maximum withstand capacity is generally extremely large for subjects with severe disabilities, and decreases as recovery progresses. For those with severe disability, the maximum tolerated capacity may exceed 200 g / day. JP2004 / 003215
• Vitamin C has a diuretic effect, but it is not a problem if pollakiuria occurs.
• Vitamin C causes aciduria, but does not cause calcium deposits that cause stones.
• Vitamin C is always autoxidized, so amino acids (cystine and cystine) and daltathione have been used to prevent autoxidation.
• amino acids cystine and cystine
• daltathione have been used to prevent autoxidation.
• large doses of cystine and cystine cause imbalance of amino acids and should not be used to suppress autoxidation of vitamin C in large doses.
• arginine is administered simultaneously with a large amount of vitamin C.
• Arginine is a basic amino acid, which is one of 20 kinds of ⁇ -amino acids existing in the living body. In humans, there are eight essential amino acids that cannot be synthesized in the body and must be ingested as food.Arginine is not contained in these amino acids, but is essential for childhood growth. However, in adults, it is classified as a semi-essential amino acid because it can be synthesized in the body. However, in recent years, the nutritional effects of arginine have been re-evaluated. It has been confirmed that metabolic disorders occur due to deficiency.
• the action of arginine in the method for preventing viral infection of the present invention is to supplement and supplement the action by vitamin C.
• administration of arginine can enhance immune function.
• Immune system cells that play a role in immune function include non-antibody-dependent neutrophils and macrophages and antibody-dependent lymphocytes, and administration of arginine enhances these functions.
• administration of arginine to rats increases the weight of the thymus and increases the ability of T cells to convert into plaques.Fracture fractures reduce both the thymus weight and the ability to blast T cells. It has been confirmed that arginine administration significantly improves the survival rate of rats that have been recovered by administration and that artificially caused peritonitis.
• Enhancement of the immune function by arginine due to the effect of the NO x to be a source of arginine (nitrogen oxides). That is, when administered to a subject arginine, NO x is generated to arginine and origins, in the NO x has the effect of expanding the blood vessels, to improve organ circulation.
• the dose of arginine will vary depending on the subject's weight, gender, age, health condition, and other conditions, but is generally 3 gZ days or more. If the desired effect is not obtained in 3 gZ days, the dosage can be increased to 6 gZ days, 9 days.
• Observations amount of NO x in urine This can be done N0 2 and N0 3 and or quantifying, or simply by tes-tape. That is, the administration of arginine, starting from the first 3 gZ Date, if the desired effect can not be obtained, by increasing the dose while observing the amount of NO x in urine, the amount of the NO x is increased If this occurs, it can be done by reducing the dose. This dose is for oral administration.
• the blood concentration of NO x Algine is not an indicator of dosage as it is quickly pooled in the nervous system and muscles.
• vitamin C and arginine are administered simultaneously, so that NO radicals generated by administration of excessive arginine are eliminated (viable) by vitamin C. Also in this regard, the combination of vitamin C and arginine is preferred.
• arginine When arginine is administered together with vitamin C to prevent viral infection by simultaneously administering vitamin C and arginine of the present invention, fibrous collagen is transformed into absorbable (soluble) collagen, thereby forming a bonded woven fiber.
• the effect of eliminating this can also be expected.
• inflammation In viral pneumonia, a type of viral infection, inflammation always occurs in the lung interstitium, causing abnormal growth of the interstitium (proliferation of acid mucopolysaccharide and collagen).
• vitamin C cleaves the sugar chain of the acidic mucopolysaccharide, softens collagen, and can also prevent lung failure due to chronic viral pneumonia.
• the cleavage of the sugar chain of the acidic mucopolysaccharide by vitamin c can be confirmed by adding vitamin C to the mucopolysaccharide and observing the viscosity with an Oswald viscometer, as the viscosity gradually decreases.
• vitamin C is covered by the coating, so there is no direct contact with arginine and no Maillard reaction occurs.
• vitamin C coated by the coating vitamin C completely coated with fats and oils can be used.
• An example of the formulation of the virus infection preventive agent is one containing 10 g of vitamin C, 3 g of arginine, and 1.5 g of RNA.
• a liquid suitable for infusion or injection can be used for the prevention of the viral infection of the present invention.
• This liquid preparation is useful when oral administration of the preparation is difficult, such as when the patient has lost consciousness due to a viral infection or when the patient is elderly. It is effective.
• the problem that arises when preparing a liquid formulation is the Maillard reaction in which amino acids react with saccharides. When the Maillard reaction occurs, it not only impairs the effect of each component but also deteriorates in taste, which is very undesirable. However, the present inventor has found that if it does not contain cystine and cystine, even if L-arginine and L-ascorbic acid are mixed in an aqueous solution, the Maillard reaction does not occur for several months. . It was also found that the addition of sugar alcohols such as xylitol and sorbitol can further extend the period until the Maillard reaction occurs.
• the present invention also relates to a virus infection preventive agent comprising vitamin C and arginine dissolved in a pharmaceutically acceptable solution and containing no cysteine.
• viruses that can prevent the infection according to the present invention are diverse, such as adeno-associated, Batai, Punyambella, California encephalitis, corona, cowpox, Koxsatsuki-ichi (A, B all types), Kreuzfurt-Jakob factor, Dengue (all types), Echo (all types), Eastern Zebra Encephalitis, Entero (68-71), EB, Hepatitis (A, B, C, D, E), Simple Herpes (1, 2), Human Cytomegalo, HHV6, Human papilloma, human palpo, human rhino, human blood, HTLV-I, HTLV-II, influenza (A, B, C), Japanese encephalitis, JC, lacrosse, LCM, measles, mumps, Murray Valley encephalitis, monkeypox, Newcastle disease, parainfluenza, polio, rabies (fixed poison), RS, rubella, Semliki forest fever, monkey immunodeficiency (S
• the method for preventing viral infection of the present invention is effective for viral infection caused by both DNA virus and RNA virus.
• it can be preferably used for coronavirus causing severe acute respiratory syndrome (SARS).
• SARS severe acute respiratory syndrome
• a 70-year-old man with influenza pneumonia was targeted.
• the subject's chest X-ray showed butter-fly-like shadows on both hilar portions, indicating that pneumonia was caused.
• Antibiotic treatment was ineffective.
• the subject received 1000 mg / kg / day of vitamin C and 3 g / day of arginine.
• Example 2 Male in their 70s
• the subjects were men in their 70s who had poor lung function.
• the subject required constant inhalation of oxygen, and visual inspection of the upper body showed a depression during inspiration of the suprasternal fossa, and auscultation showed weak breathing sounds and prolonged expiratory phase and expiration time.
• a percussion to the chest showed a drumming sound, and hyperinflation of the lungs was observed.
• Chest CT findings of the subject showed enlarged alveoli due to rupture of interstitial fibers, which is a symptom of emphysema.
• Blood gas analysis also suggests that venous blood mixing in the lungs, ie, blood mixing into the arterial system that is not involved in oxygen gas exchange in the lungs, was due to a decrease in oxygen partial pressure in the blood.
• the subject was given 100 mg OmgZk gZ of vitamin C and 3 gZ of arginine. Because it was only observed a slight effect at doses of arginine according, to observe the concentration of NO x in urine, excess of the NO x is gradually increasing doses of arginine noting that not discharged. A sufficient effect was achieved when the dose was 6 g / day. At this time, if a sufficient effect is not achieved, as long as the excess of the NO x in the urine is not discharged, it is also possible to further increase the dose of arginine to example 9 g / day.
• the formulation was administered by infusion to influenza pneumonia patients who had failed antibiotic administration. Dose, the concentration of NO x in the urine of a patient was measured by tes-tape, and the amount such that the N ⁇ x concentration does not increase.
• Vitamin C can be mass-produced and inexpensive, and arginine is also contained in large amounts in protamine, a nucleoprotein of fish sperm. It is much lower than. Also, the allowable doses of vitamin C and arginine can be easily determined, and there is little risk of side effects from these administrations, and no serious side effects are caused.
• the present invention is effective against RNA virus.
• viruses There are two types of viruses: DNA virus and RNA virus / virus.
• the former can produce an effective vaccine because the nucleotide sequence does not change easily, while the latter can change the nucleotide sequence easily, Is difficult to manufacture.
• the present invention kills the virus by directly acting on the base sequence of the virus, it is not related to the easiness of change of the base sequence, and it is possible to prevent infection by the RNA virus well.

Landscapes

• Health & Medical Sciences (AREA)
• Life Sciences & Earth Sciences (AREA)
• Chemical & Material Sciences (AREA)
• Medicinal Chemistry (AREA)
• Pharmacology & Pharmacy (AREA)
• Animal Behavior & Ethology (AREA)
• General Health & Medical Sciences (AREA)
• Public Health (AREA)
• Veterinary Medicine (AREA)
• Virology (AREA)
• Epidemiology (AREA)
• General Chemical & Material Sciences (AREA)
• Communicable Diseases (AREA)
• Oncology (AREA)
• Chemical Kinetics & Catalysis (AREA)
• Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
• Organic Chemistry (AREA)
• Dermatology (AREA)
• Molecular Biology (AREA)
• Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
• Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
• Medicinal Preparation (AREA)

Priority Applications (4)

Applications Claiming Priority (2)

Related Child Applications (1)

Publications (1)

Family

ID=34616351

Family Applications (1)

Country Status (4)

Cited By (1)

Families Citing this family (2)

Citations (6)

Family Cites Families (8)

• 2003
  • 2003-11-20 JP JP2003390695A patent/JP4671092B2/ja not_active Expired - Fee Related
• 2004
  • 2004-03-11 EP EP04719654A patent/EP1693058A4/en not_active Withdrawn
  • 2004-03-11 WO PCT/JP2004/003215 patent/WO2005049007A1/ja not_active Ceased
  • 2004-03-11 CA CA002547881A patent/CA2547881A1/en not_active Abandoned

Patent Citations (6)

Non-Patent Citations (7)

Also Published As

Similar Documents

Legal Events